Haemato AG (HM:HAEK) — Market Cap & Net Worth
Market Cap & Net Worth: Haemato AG (HAEK)
Haemato AG (HM:HAEK) has a market capitalization of $64.92 Million (€55.53 Million) as of July 22, 2026. Listed on the HM stock exchange, this Germany-based company holds position #20865 globally and #1885 in its home market, demonstrating a -1.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Haemato AG's stock price €12.80 by its total outstanding shares 5229307 (5.23 Million). See Haemato AG (HAEK) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Haemato AG Market Cap History: 2025 to 2026
Haemato AG's market capitalization history from 2025 to 2026. Data shows growth from $54.41 Million to $78.25 Million (0.00% CAGR).
Haemato AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Haemato AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HAEK by Market Capitalization
Companies near Haemato AG in the global market cap rankings as of July 22, 2026.
Key companies related to Haemato AG by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #505 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #515 globally with a market cap of $51.87 Billion USD ( CN¥354.48 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #548 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #617 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #515 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $51.87 Billion | CN¥55.57 |
| #548 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.46 |
| #617 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Haemato AG Historical Marketcap From 2025 to 2026
Between 2025 and today, Haemato AG's market cap moved from $54.41 Million to $ 78.25 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €78.25 Million | +43.82% |
| 2025 | €54.41 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of Haemato AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $64.92 Million USD |
| MoneyControl | $64.92 Million USD |
| MarketWatch | $64.92 Million USD |
| marketcap.company | $64.92 Million USD |
| Reuters | $64.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Haemato AG
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HI… Read more